These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 19622166)

  • 1. Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study.
    Zhang H; Dong B; Lu JJ; Yao X; Zhang S; Dai B; Shen Y; Zhu Y; Ye D; Huang Y
    BMC Cancer; 2009 Jul; 9():249. PubMed ID: 19622166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
    Naito S; Tsukamoto T; Murai M; Fukino K; Akaza H
    BJU Int; 2011 Dec; 108(11):1813-9. PubMed ID: 21481133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
    Bellmunt J; Maroto-Rey P; Trigo JM; Carles J; Guillem V; López-Martín JA; Antón-Torres A; Urruticoechea L
    Clin Transl Oncol; 2010 Jul; 12(7):503-8. PubMed ID: 20615828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
    Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
    J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
    Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.
    Khan G; Golshayan A; Elson P; Wood L; Garcia J; Bukowski R; Rini B
    Ann Oncol; 2010 Aug; 21(8):1618-1622. PubMed ID: 20089567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
    Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
    BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
    Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
    Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 10. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice.
    Tanigawa G; Kawashima A; Yamaguchi S; Nishimura K; Miyoshi S; Kajikawa J; Meguro N; Yosioka T; Oka T; Hara T; Takayama H; Nonomura N;
    Jpn J Clin Oncol; 2011 Nov; 41(11):1265-70. PubMed ID: 21965163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
    Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
    Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib rechallenge in patients with metastatic renal cell carcinoma.
    Nozawa M; Yamamoto Y; Minami T; Shimizu N; Hatanaka Y; Tsuji H; Uemura H
    BJU Int; 2012 Sep; 110(6 Pt B):E228-34. PubMed ID: 22332735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.
    Zheng Y; Wang F; Wu G; Zhang L; Wang Y; Wang Z; Chen P; Wang Q; Lu J; Wang Y; Li P; Wang J; Lu X; Yuan J
    Medicine (Baltimore); 2015 Dec; 94(49):e2222. PubMed ID: 26656362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study.
    Kim SH; Kim S; Nam BH; Lee SE; Kim CS; Seo IY; Kim TN; Hong SH; Kwon TG; Seo SI; Joo KJ; Song K; Kwak C; Chung J
    PLoS One; 2015; 10(8):e0135165. PubMed ID: 26308612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.
    Grünwald V; Seidel C; Fenner M; Ganser A; Busch J; Weikert S
    Br J Cancer; 2011 Nov; 105(11):1635-9. PubMed ID: 22033275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
    Rini B; Szczylik C; Tannir NM; Koralewski P; Tomczak P; Deptala A; Dirix LY; Fishman M; Ramlau R; Ravaud A; Rogowski W; Kracht K; Sun YN; Bass MB; Puhlmann M; Escudier B
    Cancer; 2012 Dec; 118(24):6152-61. PubMed ID: 22692704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
    Malouf GG; Camparo P; Oudard S; Schleiermacher G; Theodore C; Rustine A; Dutcher J; Billemont B; Rixe O; Bompas E; Guillot A; Boccon-Gibod L; Couturier J; Molinié V; Escudier B
    Ann Oncol; 2010 Sep; 21(9):1834-1838. PubMed ID: 20154303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study.
    Zhang HL; Qin XJ; Wang HK; Gu WJ; Ma CG; Shi GH; Zhou LP; Ye DW
    Oncotarget; 2015 Nov; 6(34):36870-83. PubMed ID: 26472104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.
    Di Lorenzo G; Cartenì G; Autorino R; Bruni G; Tudini M; Rizzo M; Aieta M; Gonnella A; Rescigno P; Perdonà S; Giannarini G; Pignata S; Longo N; Palmieri G; Imbimbo C; De Laurentiis M; Mirone V; Ficorella C; De Placido S
    J Clin Oncol; 2009 Sep; 27(27):4469-74. PubMed ID: 19652053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.